News

Paris (France), 07 September 2023 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M1) Series A co-led by US investment firm OrbiMed and EU-based leading investment firm Jeito Capital, with the participation of all existing seed investors (Kurma
At ESC 2023, the acute effects of the new long-acting CRF2 selective agonist COR-1167 in a rat model of heart failure with reduced ejection fraction were presented for the first time ! COR-1167 rapidly improved cardiac function through its mild positive inotropic and marked lusitropic effects after a single subcutaneous injection demonstrating that CRF2 receptor
Instead of targeting broad heterogenous chronic heart failure populations, at Corteria, we are addressing well defined heart failure subpopulations that are most likely to benefit from our treatments: learn more about Corteria Pharmaceuticals strategy and portfolio at https://lnkd.in/gncbAv4r
Corteria Pharmaceuticals team is growing with the arrival of two very valuable members: Eléonore Jouanny who will be in charge of the CMC activities of our assets and Stephane Durant des Aulnois who is our new CFO…
Francesca is a physician with 30+ years’ experience in drug development encompassing phase 1 through phase 3 registrational trials and life cycle management. Her specialized expertise is in cardio-metabolic diseases. She joined Corteria from Applied Therapeutics, a clinical-stage biotechnology company, where, as the Head of Development and later VP, Clinical and Regulatory Strategy, she
Corteria Pharmaceuticals announces closing of €12M seed financing to advance portfolio assets.